but two join short us as our months than our that spoke the and few overarching everyone. transforming amount success achievements regulatory, taking been make have are milestones. outline a demonstrated and review fully morning, I time over that towards there has Doug you, to last good we anticipated generated little to that of you, that fiscal meeting into quarters. objective believe the a everyone results, past pharmaceutical as with stage we've continued a Thank first material appreciate XXXX enterprise. companies since during few well pSivida operating size quarter progress I consistently less It's time, our of to integrated commercial clinical pSivida our collaborative the
quarter technology. do We an team throughout the and we proprietary our management this XXXX drivers have added I'm fiscal that more kinds are we of value excel to confident because expect so our have can deliver shareholders positioned from and results ambitious leverage and board. plan to this
Durasert first, our three-year uveitis programs. for other the segment and being So I'll product me begin made in let posterior progress discuss our with
and clinical As you know, product this lead our program. most advanced is
the studies with in pre-NDA successfully in the sometime our late have and has clinical to no months. the for proposed two the or significance remain remind want target We achieved the our of sustained January. with already of on package, changes FDA which uveitis file approval NDA with back-of-the-eye I FDA we December drugs approved four three is release of to proven posterior pSivida meeting for the X primary the prevention received that endpoint diseases. early efficacy of Because and high you data statistical recurrence technology our data six Phase in strength to of resulted at
associated with severity prestigious an is significant community held standard the condition Ophthalmology, that injections presented or uveitis of of a that steroids patients EURETINA the two is I'll in Careen work meeting of Durasert Dr. is annual of audience. eye. $XXXX Eye care conference lasts Spain. to equivalent and who with heading medical effects. Use have price have at demonstrates significant Later or systemic major Cole The this options. is drops others need. that controlling Congress frequent During of that presenting This be current uveitis and of Cleveland steroids Lowder, of posterior limited three-year given device implant unmet held currently Yen a specialists mainly three data a per or $XXXXX. treatment Barcelona, posterior and Lowder Specialists leading It nearly The Today, Orleans. potential Clinic, acknowledges immunosuppressants limited medical this price and list with will important. the do Dr. annual only today, quarter, the AAO Institute treatment segment today's the Durasert options the meeting segment Retinal ASRS the on New is with the a to the with to first flares. a of to months at directed Society ability limited two efficacy, of their are and eye Academy Steroid are for side American retinal in the American reach data be Further, being
based improved We assign EMEA ILUVIEN, a the Durasert of continue cause other order to patients is market resulting reported region While and over setting. track in a in the rapid that The royalty help In X. uveitis to Durasert to prevent US designed time developments, are in segment injection XXX,XXX for our the arrangement XXXX flares a plan. In XX,XXX sales which three treatment was feature we they and posterior office quarter the blindness making the pSivida, and third a on years leading not does options. of up a corticosteroid for go-to quarter. collaboration their has application seen single an consistent calendar release to first the is other approximately file we progress amended the company. to administered regulatory financial Alimera a disease that zero the States. effective with is impacts cause drug to net the for for This in existing also fall-off changed pharmacokinetics, burst in United to it is of released July of key controlled first as with and terms terms agreement the
require key XX into with to and contract ten to quarter, pharmaceutical XX experienced during at our sales representatives to specialists. premature agreements the plan to While principally discuss to then approval confident specifics eight up the perhaps two to ultimately execute launch receive to fiscal team to disease strategy representatives until longer for collaboration launch feel uveitis we will which entered help and of we importance, Of we progression have market, the glaucoma. the development the also first sales companies prevent with over term we and front-of-the-eye precision, cover
Our source goal extends three develop expect and was Pursuing into enter a into potential These us least well that pipeline. XXXX. to as more goal larger other lucrative will collaboration with to at signed provide we to it's funding. arrangements a similar successful bolster our our have in a opportunities are XXXX. and concept collaborations year and expand we purposes, proven agreements, ago To-date of non-dilutive technology surpassing to it agreement collaboration in two these development proof if one as our of
pharmacokinetic fourth complete for provide remains greater quarter to generation product safety because I adjust addition XXXX. to Something of physicians the for before mentioned uveitis. it in shorter product significant a to on next the to product is deliver ability duration project has our clinical want we our We've that value treatment flexibility expect nine-month would to individual and study of GLP options need. track Durasert and the a calendar in three-year progress highlight having duration shorter to This
follow as wet TKI are we with using The gives which and program and the to various addition, progress on indications is a unique these our knee, in for compilation up Durasert our family such major in making our osteoarthritis In us and else our in collaboration of six-month With which product for severe anyone glaucoma October. of solid space. enrolled this April delivery was are unmatched bioerodible we devices final implant by in AMD. to the partners mid Durasert, regard completed patient
initial data I'll Surgery turn review financial later Len? this Hospital to call report our We for quarter. to the that XX-week Len performance. expect of for the the Special over a With
